Virus‐like particles for vaccination against cancer
Active immunotherapy of cancer aims to treat the disease by inducing effective cellular and humoral immune responses. Virus‐like particle‐based vaccines have evolved dramatically over the last few decades, greatly reducing morbidity and mortality of several infectious diseases and expectedly preventing cervical cancer caused by human papilloma virus. In contrast to these broad successes of disease prevention, therapeutic cancer vaccines remain to demonstrate clinical benefit. Yet, several preclinical and clinical trials have revealed promising results and are paving the way for medical breakthroughs. This study reviews and discusses the recent preclinical development and clinical trials in this field.
Other Information
Published in: WIREs Nanomedicine and Nanobiotechnology
License: http://creativecommons.org/licenses/by/4.0/
See article on publisher's website: https://dx.doi.org/10.1002/wnan.1579
Funding
Qatar National Research Fund (PDRA4‐0118‐18002), Development and exploration of a novel personalized breast-cancer vaccine based on virus-like particles by incorporating tumor- specific T-cell epitopes.
Krebsforschung Schweiz (KFS‐3971‐08‐2016, KFS‐4291‐08‐2017‐R).
History
Language
- English
Publisher
WileyPublication Year
- 2019
License statement
This Item is licensed under the Creative Commons Attribution 4.0 International License.Institution affiliated with
- Hamad Medical Corporation
- National Center for Cancer Care and Research - HMC
- Interim Translational Research Institute - HMC
